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Background: Niemann-Pick disease type C (NPC) is a rare, fatal neurovisceral disorder with autosomal recessive
inheritance, and featuring striking clinical variability dependent on the age at onset of neurological symptoms.
We report data from a large cohort of 56 Czech patients with NPC diagnosed over a period of 37 years.
Methods: An observational, retrospective analysis of historic and current clinical and laboratory information was
performed among all NPC patients originating from the area of the contemporary Czech Republic and diagnosed
between 1975 and 2012. All patients with ≥1 positive diagnostic test and relevant clinical information were
included. Data on diagnostic methods (histopathological and/or ultrastructural; biochemical; genetic), clinical status
and general information on treatment were collated. Data were examined in accordance with international
guidelines for the management of NPC.
Results: Between 1975 and 1985 diagnoses were based exclusively on specific histopathological findings, often at
autopsy. Bone marrow smear (BMS) analyses have proved to be a very specific indicator for NPC and have become
an important part of our diagnostic algorithm. Filipin staining and cholesterol esterification assays became the
definitive diagnostic tests after 1985 and were applied in 24 of our patients. Since 2005, more and more patients have
been assessed using NPC1/NPC2 gene sequencing. Twelve patients were diagnosed with neonatal/early-infantile onset
NPC, 13 with the late-infantile onset form, 20 with the juvenile onset form, and nine with the adolescent/adult onset
form. Two diagnosed patients remained neurologically asymptomatic at study completion. Nineteen patients were
siblings. Causal NPC1 mutations were determined in 38 patients; two identical NPC2 mutations were identified in one
patient. In total, 30 different mutations were identified, 14 of which have been confirmed as novel. The frequency of
individual mutated NPC1 alleles in our cohort differs compared with previous published data: the most frequent mutant
NPC1 allele was p.R1186H (n = 13), followed by p.P1007A (n = 8), p.S954L (n = 8) and p.I1061T (n = 4).
Conclusions: These data demonstrate the evolution of the diagnostic process in NPC over the last four decades. We
estimate the contemporary birth prevalence of NPC in the Czech Republic at 0.93 per 100,000.
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Niemann-Pick disease type C (NPC) is a rare genetically
and clinically heterogeneous neurovisceral lysosomal storage
disease associated with progressive, disabling neurological
symptoms and premature death in most patients [1-3]. NPC
usually occurs sporadically, and is inherited in an autosomal
recessive fashion. It has been estimated to affect one case
in every 100,000–120,000 live births [1,2,4,5].
The disease presents with striking variability. Most
cases are recognised during childhood, but increasing
numbers of patients are now being diagnosed with
adolescent or adult onset of symptoms [6]. Data indicate
that clinical symptomatology and disease progression in
NPC are both markedly affected by the age at onset of
neurological manifestations [2,7,8]. Patients are therefore
categorized by age at onset of neurological manifesta-
tions based on early-infantile (<2 years), late-infantile
(2 to <6 years), juvenile (6–15 years) and adolescent/
adult-onset forms (>15 years) [8]. These categories are
considered useful for the evaluation of disease course
and responses to therapy [1].
Knowledge of the genetic causes, biochemical mecha-
nisms, and natural history of the disease has helped greatly
in improving diagnosis over the last two decades. How-
ever, the non-specific nature of many signs and symptoms,
and the as yet incomplete characterization of underlying
disease pathophysiology still represent significant hurdles
to the timely detection and diagnosis of NPC [1,6,9]. Data
from the largest international registry for NPC patients to
date indicate marked delays between onset of initial
neurological manifestations and diagnosis [10].
While expert consensus only distinguished NPC as a
specific disorder separate from Niemann-Pick disease types
A and B (NPA and NPB, which result from sphingomyeli-
nase deficiency) in 1982 [11], experienced pathologists
have been able to define NPC through complex histo-
pathological analysis of key organs (especially brain, spleen
and liver) at autopsy since the 1970s. Indeed, up to the late
1980s patients were exclusively diagnosed by means of
histology, histochemistry and electron microscopy with a
comprehensive assessment of all clinical data [12-15].
After definitive animal modelling studies in the mid-
1980s, several research groups showed that NPC is a lipid
trafficking disorder featuring dysregulation of intracellular
lipid transport and metabolism [16-21]. As a result, the
filipin staining test, which visualizes characteristic peri-
nuclear accumulation of cholesterol-filled lysosomes in
cultivated fibroblasts, with or without supporting evidence
from cholesterol esterification assays, became regarded
as the gold standard technique for diagnosing NPC
[1,8]. Both methods are very specialized and labour-
intensive. Similar to other diagnostic techniques in
NPC, they also show some limitations, particularly in
patients showing a ‘variant’ biochemical phenotype [1,8].In addition, available data suggest that the filipin test has
limited specificity [22].
The NPC1 gene, which is associated with 95% of cases
of NPC, was characterized in 1997 [23,24]; the NPC2
gene was characterized soon after [25]. The number of
NPC patients diagnosed based on genetic evidence of
NPC1 or NPC2 gene mutations has increased markedly
over the last decade due to methodological advances and
improved suitability for pre-natal testing and genetic
counselling [8]. Clinical scoring systems such as the
NP-C Suspicion Index (SI) have also been developed to
further accelerate detection and diagnosis [26].
All techniques used in the diagnostic process in NPC
have their limits (Table 1). The diagnostic process for NPC
is therefore multidisciplinary by necessity, taking into
account all available data from clinical symptomatology
assessments, histological and electron microscopy tests,
and biochemical and molecular genetic studies.
Previous studies in cohorts of selected patients from
the UK, Spain, France, and the USA have provided clinical
descriptions of NPC [27-30], and have looked into possible
genotype–phenotype correlations [24,30-33]. Here, we
provide a comprehensive description of a large cohort of
NPC patients originating from the area of the contempor-
ary Czech Republic, with an emphasis on how diagnostic
procedures have evolved in line with advances in know-
ledge on the pathogenesis of the disease during the last
four decades.
Materials and methods
Study design and patients
This study was an observational, retrospective analysis
of historic and current information among Czech NPC
patients diagnosed between the years 1975 and 2012. All
patients with at least one positive, confirmed diagnostic
test and with further relevant clinical information available
at the Institute of Inherited Metabolic Diseases in Prague
were included. This is the only institution that performs
diagnostic procedures on lysosomal storage diseases in the
Czech Republic.
All available medical reports from identified NPC pa-
tients were checked by a clinician familiar with the disease.
Relevant clinical data, histopathological and/or ultrastruc-
tural findings, biochemical measurements and results of
genetic testing were collated. Specific clinical and laboratory
findings from siblings or other relatives were also evaluated
in relevant cases (e.g. in cases where family members had
similar symptoms or identified NPC, prolonged jaundice
and/or respiratory failure in the postnatal period).
All information was accessed in accordance with applic-
able laws and ethical requirements for the study period
concerned. All procedures, including informed consents for
molecular genetic analyses, were conducted in accordance
with the ethical standards of the responsible committee on
Table 1 Reliability and limitations of diagnostic methods in NPC
Diagnostic method Sensitivity Specificity Comment
Clinical evaluation Low-to-moderate Usually low Depends on the form and stage of disease and
experience of clinician
Histology, histochemistry and electron
microscopy of appropriate tissues (bone
marrow smear, spleen, liver, brain)
Not exactly defined, in particular
tissue probably moderate, at
autopsy moderate-to-high
High Must be performed by experienced
histopathologist*
Filipin staining test (alone or in
combination with LDL-cholesterol assay)
High (but not absolute) High (but not
absolute)
Must be performed by experienced laboratory.
Less reliable in persons with ’variant biochemical
subtype”. Similar results in some other IEM**.
Molecular genetic analysis High (but not absolute) High (but not
absolute)
Only one mutation identified in some patients;
difficult decision regarding pathogenicity of novel
private mutations in NPC genes
*See references [12-15]; **inborn errors of metabolism.
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Helsinki Declaration of 1975, as revised in 2000. Informed
consent for genetic analysis in some deceased patients was
obtained from their legal representatives during genetic
counselling for affected families. In cases where genetic
information has been included in previous publications,
literature citations are provided [33,34].
Clinical assessments
The types of collated clinical data included information on
key signs and symptoms of NPC [1]. Where available, the
following were assessed: neurological signs (e.g. oculo-
motor abnormalities including vertical supranuclear gaze
palsy (VSGP), ataxia, dysarthria, dysphagia, dyskinesia,
spasticity); neuropsychiatric status (e.g. psychomotor
delay and/or regression, learning disabilities, psychosis,
behavioural abnormalities, cognitive decline); systemic
symptoms (e.g. any evidence of organomegaly, lung dis-
ease or neonatal cholestatic disease); relevant imaging
findings (e.g. brain MRI, abdominal ultrasonography);
results from neurophysiological studies; plasma chito-
triosidase activity. As detailed information from MRI
and neurophysiological methods was available only in
some patients diagnosed in the last decade, these items
were not addressed in this analysis. Data from patients
treated with miglustat were examined in accordance
with defined international guidelines for the diagnosis,
assessment and subsequent follow-up of NPC [1,8].
Histopathological and ultrastructural analyses
Bone marrow smears
Bone marrow smears (BMS) were stained by the Giemsa-
Romanovsky method and examined for macrophage
cytology. Lipopigments and lipids were analysed in an
unstained smear mounted in aqueous medium. Auto-
fluorescent lipopigment was detected by epifluorescence
microscopy using a fluorescence filter BV-2A (Ex 400–
440 nm/DM 455/BA 470) on a Nikon E800 microscope.
Lipids were examined for birefringence in polarized light.
Activities of non-specific neutral esterases (with α-naphtylacetate/hexazonium para-rosaniline) and acid phosphatase
(with naphthol ASBI phosphate/hexazonium para-rosanil-
ine) were used for evaluation of the macrophage population
and the activated lysosomal system, respectively.
Additional histochemical methods were performed in
some cases, including detection of: total phospholipids
(with iron hematoxylin); sphingomyelin (iron hematoxylin
after alkaline hydrolysis); acidic lipids (with cresyl violet);
glycosphingolipids (with periodic acid-Schiff); and apolar
components (with Sudan Black B) [14,15].
Liver biopsies
Liver biopsy samples were divided into three pieces. One
was rapidly frozen for histochemical analyses including
detection of phospholipids, sphingomyelin, glycosphingo-
lipids, acidic lipids, and apolar components and lipopig-
ments [13], one was fixed with 4% formaldehyde and
embedded in paraffin for routine histology and immuno-
histochemistry, and one was processed for electron micros-
copy (see ‘Electron microscopy’ section).
Brain and visceral organs
Samples of brain and viscera from autopsy examinations
were assessed using formol-fixed, paraffin-embedded tissue
blocks cut into 4 μm-thick sections and stained using
standard histological techniques. Brain samples were proc-
essed according to Spilmayer’s scheme, with sections
stained using hematoxylin eosin, Nissl, Bodian and Kluver-
Barrera methods. A basic set of immunohistochemical
methods were applied on paraffin sections of brain for the
detection of: glial fibrillary acidic protein (GFAP); microglial
marker CD68; neuron-specific nuclear protein (NeuN);
neurofilament protein; and ubiquitin. Neurofibrillary tan-
gles were analysed using an anti-phosphorylated tau protein
antibody. Membranous (LAMP1, LAMP2) and luminal
(cathepsin D) lysosomal markers were assessed to gauge
lysosomal storage expansion.
For lipid detection, a battery of histochemical methods
was applied on 7–12 μm-thick cryostat sections cut from
fresh tissue specimens quenched in petrol ether cooled
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nitrogen. The principal detection methods included: auto-
fluorescence, birefringence, phospholipid detection with
iron hematoxylin with or without alkaline pre-hydrolysis,
PAS method for detection of glycolipids, cresyl violet for
detection of acidic groups, and apolar lipids and lipopig-
ments stained with Sudan Black B [12]. Cholesterol was
analysed according to the method of Emeis et al. [12].
Electron microscopy
Ultrastructural analysis of neuronal and non-neuronal tis-
sues including skin biopsies (if performed) was conducted
using electron microscopy. Tissue samples were fixed with
10% buffered paraformaldehyde and 1% osmium tetraoxide,
dehydrated and embedded in Epon-Arraldite mixture. Thin
sections were double-contrasted with uranyl acetate and
lead nitrate, and examined using a TESLA 500 electron
microscope [12].
Biochemical analyses
Biochemical diagnostic tests in fibroblast cultures were
performed based on at least one of three methods
referred chronologically depending on the time of
technique introduction: 1) measurement of intracellular
esterification of exogenous non-lipoprotein 3H-cholesterol,
expressed as a percentage of total intracellular 3H-choles-
terol present as cholesteryl esters after 24 hours [17] (two
patients); 2) measurement of intracellular esterification
of exogenous lipoprotein-derived LDL-cholesterol [18,19];
3) evaluation of intracellular accumulation of unesterified
cholesterol after challenge with lipoprotein-enriched med-
ium, visualized by histochemical staining with filipin
[19,20]. Tests 2 and 3 were performed simultaneously
at the Laboratoire de Neurochimie, Centre Hospitalier
Lyon-Sud in France by Dr M.T. Vanier, MD, PhD.
Final results were interpreted in terms of the ‘classical’,
‘intermediate’ or ‘variant’ biochemical phenotypes. Results
supporting a ‘classical’ biochemical phenotype comprised
a very strong accumulation of unesterified cholesterol
in perinuclear vesicles coupled with a low amount of
cholesteryl 3H-oleate formed in specific conditions
(<100 pmol/mg/4.5 hours; control level 2950 ± 1200
pmol/mg/4.5 hours). A ‘variant’ biochemical subtype was
characterized by moderate accumulation of unesterified
cholesterol and a relatively high formation of labelled
cholesteryl ester (337–1195 pmol/mg/4.5 hours). If the
results of both tests were abnormal but there was a
discrepancy between filipin staining findings and LDL-
cholesterol esterification data, patients were categorized
as having an ‘intermediate’ biochemical phenotype.
Genetic analyses
Genomic DNA was extracted from samples of peripheral
blood into EDTA-containing tubes or from skin fibroblastcultures using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. In the case of previously described adult patient,
phenol–chloroform extraction of DNA was used in
formalin-fixed, paraffin-embedded (FFPE) tissues as previ-
ously described [34]. RNA was extracted from samples of
peripheral blood into EDTA-containing tubes or from
cultured fibroblasts using the Blood Total RNA Isolation Kit
with on-column genomic DNA removal by DNase I (MO-
BIO, Carlsbad, CA, USA). Complementary DNA (cDNA)
was synthesized using a commercial ThermoScript™ RT re-
verse transcriptase kit with oligo(dT) (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
Mutation analysis was based on direct sequencing of PCR
or RT/PCR products of the NPC1 (GenBank NC_000018.9;
NM_000271.4) and NPC2 (GenBank NC_000014.8; NM_0
06432.3) genes using a Pharmacia AlfExpress Sequencer
and later capillary sequencers (ABI Prism 3100-Avant or
3500xL Genetic Analyzer; Life Technologies, Carlsbad, CA,
USA). The primers used for sequencing were generated
in house: their specifications are available upon request.
Detected mutations are described according to nomencla-
ture guidelines of the Human Genome Variation Society
(HGVS: http://www.hgvs.org/mutnomen/).
The copy number of NPC1 and NPC2 coding exons was
determined by multiplex ligation probe amplification
(MLPA) assay using a SALSA MLPA kit P193-A1 NPC1
(MRC-Holland, Amsterdam, the Netherlands). The patho-
genicity of novel missense variations was evaluated in
silico using prediction software tools SIFT [35], PolyPhen-
2 [36], PMut [37] and MutationTaster [38]. To exclude
common polymorphisms, detected gene variations were
also compared with databases of the National Center for
Biotechnology Information (NCBI; http://www.ncbi.nlm.
nih.gov/), Ensembl (http://www.ensembl.org/), 1000 Ge-
nomes (www.1000genomes.org/) and the Exome Variant
Server (http://evs.gs.washington.edu/EVS/).
Data analysis
This was an observational study so all data were summa-
rized in a descriptive fashion. No statistical testing was
performed. Data on patient and disease characteristics
and definitive diagnostic methods were stratified accord-
ing to established forms of neurological disease in NPC
[2,8]. The NP-C SI score was applied retrospectively in




A total of 56 patients, 30 (54%) females and 26 (46%)
males, were diagnosed with NPC in the Czech Republic
between 1975 and 2012. Fifty-five patients were diag-
nosed with NPC1 and one was diagnosed with NPC2.
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families were relatives (siblings and cousins). The overall
median age of patients at presentation of the first symptom
was 5 years, and the median age at diagnostic assessment
was 9 years. Patient and disease characteristics data from
the whole Czech Republic NPC cohort are summarized in
Tables 2,3,4,5,6 according to age at onset of neurological
manifestations.
Primary and secondary diagnostic tests
Figure 1 summarizes the pathways to confirmed diagnoses
in this cohort, stratified by 10-year intervals. Overall, diag-














Neonatal rapidly fatal form
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4 F 0 1976 5y (†) HSm (1y) PMRt (6 m)
5y
5 M 0 1981 5y (†) NJa, HSm (1 m) PMRt (1y)
5y




7 F 0 1985 11y (†) mild HSm (1 m) MRt (1y)
1y
8 F 0 1990 4y (†) HSm (20 m) PMRg (20 m)
3y




10 F S of
10/T3
1997 ?(†)/5y NJa, HSm (1 m) SRt (22 m)
5y
11 F 0 2001 6y (†) Sm (2y) PMRg, A (22 m)
3y
12 F S of
13/T3
2010 6y HSm (2y) PMRt, A (18 m)
2y
A ataxia, AT autopsy; B brother, BMS bone marrow smear; CE non-LDL-cholesterol esterificat
classical biochemical subtype using filipin staining + CEL, G gender, Hp hepatopathy, HSm h
not detected, NR not reported, NJa neonatal jaundice, P order of patient in the age-at-onset
sibling, Sm splenomegaly, SRt speech retardation, T table, y years, † patient deceased, †genot
9), ‡patient described previously [33], ††genotype determined indirectly based on parents’ gen
highlighted in bold font, and italics indicate decisive diagnostic method or methods (if they wmethods (histopathological, biochemical, genetic) in 18
patients, two methods in 20 patients, and one method in
18 patients. Twenty-two patients (39%) were diagnosed
with NPC primarily based on histopathological infor-
mation; 16 diagnoses were obtained at autopsy, mainly
between 1975 and 1984. A total of 16 patients (29%)
were diagnosed based on positive filipin staining results
with supportive LDL-cholesterol esterification or on
results of a non-LDL-cholesterol esterification test. In both
cases, biochemical data were considered in conjunction
with suggestive findings from BMS. Five patients were
diagnosed on the basis of filipin/LDL-cholesterol esteri-












Y ND Y ND
Y ND Y (AT) ND
ND ND Y (AT) c.1261C>T/c.3614C>G††
p.Q421*/p.T1205R
ND ND Y (AT) ND
Y ND Y (AT) c.3557G>A/NDT
p.R1186H/NDT
Y ND Y (AT) ND
Y Y (CE) Y c.3182T>C/c.3591+1G>A
p.I1061T/splice
Y Y (F/C) ND c.1812dupT/c.3558delC
p.A605Cfs*1/p.A1187Rfs*54
Y Y (F/C) Y (AT) NPC2: c.58G>T/c.58G>T
p.E20*/p.E20*‡
Y Y (F/C) ND c.826T>C/c.3557G>A
p.Y276H/p.R1186H
Y Y (F/C) Y (AT) c.3557G>A/c.3614C>A
p.R1186H/p.T1205K
ND ND ND c.2196dupT/c.3557G>A
p.P733Sfs*9/p.R1186H
ion test; CEL LDL-cholesterol esterification test; Cs cousins, dg diagnosis, F female, F/C
epatosplenomegaly, m months, M male, MRt motoric retardation, ND not done, NDT
category, PMRg psychomotoric regression, PMRt psychomotoric retardation, S sister, Sb
ype refers to the NPC1 gene (patients 1–8 and 10–12), and to the NPC2 gene (patient
otype. *translation stop codon in 1-letter amino acid code. Note: novel mutations are
ere performed simultaneously or in quick succession).
Table 3 NPC patients with late-infantile (LI) form of disease





















1 M B of 2/T3 1975 11y (†) NR PMRt (3 y) ND ND Y (AT) ND
DPM
2 M B of 1/T3 1975 9y (†) NR SRt, Epi (3 y) ND ND Y (AT) ND
DPM
3 M 0 1975 8y (†) NR PMRg, Epi (3 y) ND ND Y (AT) ND
DPM
4 F S of 14/T4 1975 ? (†)/4y HSm (4 m) PMRg, A (4y) ND ND Y ND
4y
5 M 0 1981 5y (†) HSm (1 m) PMRt (3y) Y ND Y (AT) c.1421C>T/c.3557G>A††
3y p.P474L/p.R1186H




7 F 0 1990 11y (†) HSm (4y) A, Ds, GCt (4 y) Y Y (F/V) ND c.1029dupG/c.3019C>G
8y p.S344Vfs*35/p.P1007A
8 F 0 1993 12 (†) y NJa (1 m) A, Ds, Epi (4y) Y Y (F/C) ND c.3182T>C/NDT
10y p.I1061T/NDT
9 M 0 1995 22y (†) HSm (5y) PMRt (5y) Y Y (F/I) ND c.3019C>G/c.3557G>A
5y p.P1007A/p.R1186H
10 M B of 10/T2 1998 ?(†) /4y HSm (1 m) SRt (4 y) ND Y (F/C) ND c.826T>C/c.3557G>A
4y p.Y276H/p.R1186H
11 M 0 2004 10y HSm (7 m) A, GCt (4y) ND Y (F/C) ND c.3182T>C/c.3557G>A
4y p.I1061T/p.R1186H
12 M 0 2008 12 (†) Sm (6y) A, PMRg (3y) Y ND ND c.3557G>A/c.3557G>A
6y p.R1186H/p.R1186H
13 M B of 12/T2 2009 6y (†) NJa (1 m) A, GCt (4y) Y ND ND c.2196dupT/c.3557G>A
4y p.P733Sfs*9/p.R1186H
A ataxia, AT autopsy, B brother, BMS bone marrow smear, CE non-LDL-cholesterol esterification test, CEL LDL-cholesterol esterification test, Cs cousin, dg diagnosis,
DPM delayed post-mortem examination (in preserved tissues, Ds dysartria, Epi epilepsia, F female, F/C classical biochemical subtype using filipin staining + CEL, F/I intermediate
biochemical subtype using filipin staining + CEL, F/V variant biochemical subtype using filipin staining + CEL, G gender, GCt gelastic cataplexy, HSm hepatosplenomegaly,
m months, M male, ND not done, NDT not detected, NJa neonatal jaundice, NR not reported, P order of patient at the category; PMRg psychomotoric regression, PMRt
psychomotoric retardation, S sister, Sb sibling, Sm splenomegaly, SRt speech retardation, T table, y years, Y Yes, † patient deceased, ††genotype determined indirectly based
on parents’ genotype, *translation stop codon in 1-letter amino acid code. Note: novel mutations are highlighted in bold font, and italics indicate decisive diagnostic
method or methods (if they were performed simultaneously or in quick succession).
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analyses, and two were diagnosed based on genetic ana-
lyses alone.
Two pathogenic mutations were detected in the NPC1
gene in 38 cases from 33 families, and in the NPC2 gene
in one case. NPC diagnoses based on histopathological
or biochemical methods were later confirmed by genetic
analysis in 26 patients, two of which were established
indirectly from parental studies. Two patients (patient 5
in Table 2 and patient 8 in Table 3) were diagnosed by
other methods; only one mutation in the NPC1 gene has
so far been detected in these cases.Median delays between first symptom and diagnosis
appeared fairly stable among patients with the neonatal/
early infantile form of NPC (1–2 years), but tended to
decrease over time in those with the late-infantile form
(from 9 years between 1975–1984 down to 3 years over
the last two decades). Conversely, diagnostic delays among
patients with the juvenile form showed a high degree of
variability (average 7 years). Eight patients with the adoles-
cent/adult form were diagnosed in the last two decades
(median diagnostic delay 6 years) compared with only one
patient from this category in the previous two decades
(diagnostic delay 20 years).
Table 4 NPC patients with juvenile (J) form of disease





















1 F 0 1975 29y (†) NR A, Ds (13y) ND ND Y(AT) ND
29y
2 M 0 1976 11y (†) NJa, HSm (1 m) PMRg (8y) ND ND Y(AT) ND
11y
3 F S of 4/T4 1980 14y (†) NR Sp, Epi (7y) ND ND Y(AT) ND
14y
4 M B of 3/T4 1981 20y (†) Sm (9y) LDs, Epi (9y) Y ND Y ND
9y
5 F 0 1981 24y (†) HSm (8y) LDs, Tr (8y) Y ND Y ND
10y
6 F S of 7/T4 1989 19y (†) NR A, PMRg (7y) Y Y(F/C) Y c.2196dupT/c.2861C>T
7y p.P733Sfs*9/p.S954L
7 F S of 6/T4 1989 33y (†) HSm (5y) A, Ds (9y) Y ND ND c.2196dupT/c.2861C>T
9y p.P733Sfs*9/p.S954L
8 F 0 1997 24y (†) NR Sp, Ds (14y) ND ND Y(AT) ND
24y
9 F 0 1997 18y HSm (9 m) A, Ds, BDs (7y) Y Y(F/C) ND c.1421C>T/c.2072C>T
1y p.P474L/p.P691L
10 F S of 2/T5 1997 38y Sm (21y) A, Ds (13y) ND Y(F/C) ND c.1210delC/c.1990G>A
21y p.R404Gfs*45/p.V664M
11 M 0 1998 28y NR Epi, CDc (13y) Y Y(F/V) ND c.1232G>C/c.3019C>G
13y p.R411P/p.P1007A
12 M Cs of 20/T4 1998 21y Sm (4y) Ds (14y) ND Y(F/I) ND c.2861C>T/c.3557C>A
5y p.S954L/p.R1186H
13 M 0 1999 ?(†)/17y Sm (17y) LDs (7y) Y Y(F/I) ND c.2849T>G/c.3019C>G
17y p.V950G/p.P1007A
14 F S of 4/T3 2000 27y (†) Sm (7y) PMRg (7y) ND Y(F/V) Y(AT) c.352_353delAG/
c.3019C>G
27y p.Q119Vfs*7/p.P1007A
15 F 0 2000 27y Sm (13y) LDs, A (9y) Y Y(F/I) ND c.1812dupT/c.2861C>T
13y p.A605Cfs*1/p.S954L
16 F 0 2002 25y (†) NR LDs, A, Dk (13y) ND ND Y(AT) c.1028G>A/c.3019C>G
25y p.G343E/p.P1007A
17 M 0 2003 35y Sm (23y) A, Ds (14y) Y Y(F/C) ND c.2861C>T/c.3557G>A
24y p.S954L/p.R1186H
18 M B of 5/T5 &6/
T5
2005 23y Sm (14y) LDs,Ds (14y) ND Y(F/V) ND c.2780C>T/c.2780C>T
14y p.A927V/p.A927V
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Table 4 NPC patients with juvenile (J) form of disease (Continued)
19 M 0 2006 27y Sm (19y) Ds, Epi (13y) Y ND ND c.1232G>C/c.2861C>T
19y p.R411P/p.S954L
20 F Cs of 12/T4 2007 23y Sm (18y) Ds, A (13y) Y ND ND c.2861C>T/c.3557G>A
18y p.S954L/p.R1186H
A ataxia, AT autopsy, B brother, BDs behaviour disorder, BMS bone marrow smear, CDc cognitive decline, CE non-LDL-cholesterol esterification test, CEL LDL-cholesterol
esterification test, Cs cousin, dg diagnosis, Dk dyskinesia, Ds dysarthria, Epi epilepsia, F female, F/C classical biochemical subtype using filipin + CEL, F/I intermediate
biochemical subtype using filipin + CEL, F/V variant biochemical subtype using filipin + CEL, G gender, HSm hepatosplenomegaly, LDs learning disability, m months,
M male, ND not done, NJa neonatal jaundice, NR not reported, PMRg psychomotoric regression, P order of patient at the category, S sister, Sb sibling, Sm splenomegaly,
Sp spasticity, T table, Tr tremor, y years, Y yes, † patient deceased, *translation stop codon in 1-letter amino acide code. Note: novel mutations are highlighted in bold
font, and italics indicate decisive diagnostic method or methods (if they were performed simultaneously or in quick succession).
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Neonatal rapidly fatal form
Three patients had the severe neonatal, rapidly fatal
form (Table 2). The first patient suffering from the neo-
natal form manifested in the first 2 weeks of life with
direct hyperbilirubinemia, progressive hepatopathy and
prominent hepatosplenomegaly. Liver and bone marrow
biopsies were performed at age 2 months with findingsTable 5 NPC patients with adolescent/adult (A) form of disea
P G Sb/Cs Year
of dg
Age at death








1 F 0 1980 46y (†) NR Tr, CDc, Dk (2
46
2 M B of
10/T4
2000 31y (†) Sm (22y) CDc, MDs (18
23
3 M 0 2001 34y (†) Sm (31y) SCH (16y)
31
4 F 0 2004 54y (†) Sm (54y) NR
54
5 F S of
6/T5
2005 35y (†) Sm (27y) DP (23y)
& 18/T4 27
6 F S of
5/T5
2005 27y Sm (20y) SCH (16y)
& 18/T4 20
7 F 0 2007 70y Sm (64y) A, Ds, Dph (57
64
8 F 0 2010 32y Sm (25y) A, Dk (16y)
28
9 F 0 2012 26y Sm (24y) LDs (16y)
24
A ataxia, AT autopsy, B brother, BMS bone marrow smear, CDc cognitive decline, CE n
cousin, dg diagnosis, Dk dyskinesia, DP depression, Dph dysphagia, Ds dysarthria, F fem
subtype using filipin + CEL, G gender, LDs learning disability, M male, MDs memory disord
S sister, Sb sibling, SCH schizophrenia, Sm splenomegaly, T table, Tr tremor, Y yes, y years,
in 1-letter amino acid code. Note: novel mutations are highlighted in bold font, and ita
simultaneously or in quick succession).supporting a diagnosis of NPC. No other information
was available. Direct hyperbilirubinemia was also found
in his younger brother at the age of 2 weeks. Prominent
hepatomegaly with mild splenomegaly was described
shortly afterwards. Surgery for suspected pylorostenosis
was performed at age 2 months, with a subsequent revi-
sion for volvulus. This patient did not recover after the












6y) ND ND Y (AT) ND
y) Y Y (F/C) ND c.1210delC/c.1990G>A
p.R404Gfs*45/p.V664M
Y ND Y (AT) c.2712delG/c.2861C>T
p.Q905Rfs*30/p.S954L
ND ND Y (AT) c.1997G>A/c.2882A>G
p.S666N/p.N961S‡
Y Y (F/V) ND c.2780C>T/c.2780C>T
p.A927V/p.A927V
ND Y (F/V) ND c.2780C>T/c.2780C>T
p.A927V/p.A927V
y) Y ND Y c.2974G>C/c.3182 T>C
p.G992R/p.I1061T
Y ND ND c.1028G>A/c.2198C>G
p.G343E/p.P733R
Y ND ND c.3019C>G/c.3592-7_3592-
3delCTTTT
p.P1007A/splice
on-LDL-cholesterol esterification test, CEL LDL-cholesterol esterification test, Cs
ale, F/C classical biochemical subtype using filipin + CEL, F/V variant biochemical
er, ND not done, NR not reported, P order of patient at the age-at-onset category,
† patient deceased, ‡patient described previously [34]; *translation stop codon
lics indicate decisive diagnostic method or methods (if they were performed
Table 6 NPC patients with isolated splenomegaly, without neuropsychiatric symptoms
P G Sb/
Cs
Year of dg Age at death


















1 M 0 2009 6y NJa, Sm (3 m) NR Y ND ND c.3557G>A/c.3557G>A
1y p.R1186H/p.R1186H
2 M 0 2011 6y HSm (3y) NR ND ND ND c.2801G>A/c.2861C>T
3y p.R934Q/p.S954L
AT autopsy, BMS bone marrow smear, CE non-LDL-cholesterol esterification test, CEL LDL-cholesterol esterification test, Cs cousin, dg diagnosis, G gender,
HSm hepatosplenomegaly, M male, m months, ND not done, NJa neonatal jaundice, NR not reported, P order of patient at the category, Sm splenomegaly, y years,
Y yes. Note: italics indicate decisive diagnostic method or methods (if they were performed simultaneously or in quick succession).
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in his liver, BMS, and examination of autoptic tissues. In
the third male, progressive neonatal cholestatic jaundice
and hepatosplenomegaly were described. Diagnostic
liver biopsy at the age of 6 weeks was complicated by
hemoperitoneum, and the patient died several days
later. Histopathological examination of autoptic tissues
and secondary DNA analysis of the NPC1 gene con-
firmed NPC. No neurological symptoms were described
in the available reports of any of these three patients.
Early-infantile form
Psychomotor retardation or stagnation/regression between
6 months and 2 years of age were the most common symp-
toms among nine patients with early-infantile onset disease
(Table 2). Four patients (patients 5, 6, 7 and 10) had neo-
natal hepatosplenomegaly and/or prolonged neonatal
jaundice. By approximately 2 years of age the leadingFigure 1 Definitive diagnostic methods for NPC in the Czech Republic
calculated relative to total number or patients per time period. AT, autopsy an
F, filipin test; G, genetic analysis; HP histopathological methods.symptoms were ataxia and speech retardation, after which
rapidly progressing neurological manifestations were seen,
which included gelastic seizures/cataplexy, oculomotor
abnormalities, dysphagia and spasticity. Most of these
patients died at approximately 5 years of age due to respira-
tory complications.
In addition, the only patient with NPC2 (patient 9,
Table 2), reported previously [33,39], was included in
the early infantile-onset group. This female was born
with a delivery complicated by mild asphyxia (Apgar
score 3-8-9), and tachypnoea, poor feeding and failure
to thrive were observed during the first year of life. Mild
psychomotor retardation, central hypotonia and moderate
hepatosplenomegaly were described at the age of 1 year,
at which point chest X-ray showed lung infiltration and
secondary emphysema. Progressive dystrophy, marked
hepatosplenomegaly, spasticity and mental decline devel-
oped during the second year of life. Lung disease gradually(1975–2012). *Percentages of patients with each diagnostic pathway
alyses; BMS, bone marrow smear; CE, cholesterol esterification assays;
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became oxygen dependent. She died aged nearly 4 years of
age due to global respiratory insufficiency.
Late-infantile form
Thirteen patients had late infantile-onset NPC (Table 3).
The median age at onset of initial symptoms was 2 years.
Presenting neurological manifestations included general
psychomotor retardation/regression, retardation of speech
development, epilepsy, gelastic seizures/cataplexy, ataxia
and dysarthria. Four patients (patients 5, 8, 10 and 13,
Table 3) had a history of neonatal hepatosplenomegaly
and/or prolonged neonatal cholestatic jaundice. VSGP
was recorded at an advanced stage of disease only in some
of the older reports (together with progressive cognitive
and motoric decline), but was recorded more frequently
among patients diagnosed in the last decade. Most patients
in this age-at-onset subgroup died between 8 and 12 years
of age (range 6–19 years), again mostly due to respiratory
complications.
Juvenile form
Twenty patients had the juvenile-onset form of NPC
(Table 4), among whom 10 presented between 7 and
9 years of age with one or more of the following neuro-
logical and/or psychiatric signs: psychomotor regression,
learning disabilities, behaviour disorder, dysarthria, ataxia,
balbuties, epilepsy and spasticity. Ten older patients from
this category presented between 13 and 15 years of age with
ataxia, dysarthria, cognitive decline, learning disability and
epilepsy. Gelastic cataplexy was often present in the youn-
ger patients later in the course of the disease. In two cases
(patients 9 and 12, Table 4) hepatosplenomegaly or isolated
splenomegaly led to the eventual detection of NPC before
the appearance of neuropsychiatric manifestations. VSGP
and saccadic abnormalities were rarely documented in
patients diagnosed before the year 2000, but were often
noted in medical reports over the last 10 years. The
median age of the first symptoms was 9 years.
Most patients with this age-at-onset form of NPC died
in the third decade of their life due to respiratory compli-
cations and secondary infection: the oldest living patient is
a female aged 38 years (patient 10, Table 4) who scores 18
points on the NPC disability scale [28].Adolescent/adult form
Nine patients had initial neurological or psychiatric signs
aged >15 years, and were categorized with the adolescent/
adult-onset form of NPC (Table 5). The median age of
the first symptoms was 18 years. Some younger patients
from this group (patients 2, 8 and 9, Table 5) originally
presented with ataxia, dyskinesia, worsening of learning
ability and memory disturbances, respectively. Thesesymptoms were followed by VSGP, dysarthria and dyspha-
gia. One female patient (patient 1, Table 5) presented with
cognitive deterioration, tremor and dystonia/dyskinesia
starting at 26 years of age, with progressive worsening
thereafter. Three patients had initial psychiatric diagnoses
(two with schizophrenia, one with depression). While two
of these cases exhibited subsequent progressive cognitive
decline, ataxia, dystonia, dysarthria, dysphagia and VSGP
(patients 3 and 5, Table 5), one (patient 6, Table 5) re-
mained free of neurological manifestations at the com-
pletion of this study, with only a fluctuating course of
psychosis present. One female patient (patient 4, Table 5)
died due to a thromboembolism, but the presence of NPC
was confirmed based on post-mortem analyses of her liver,
spleen and brain [34]. The oldest patient in this cohort
(patient 7, Table 5) was diagnosed by chance following
examination of her spleen after splenectomy; further ana-
lyses revealed that she had been under neurological care
for ≥7 years related to spasticity, ataxia, dysarthria and dys-
phagia, which had previously been ascribed to multisyste-
mic atrophy – she was later found to have VSGP. Overall,
four patients from this age-at-onset subgroup are still alive.
Asymptomatic patients
Two young male patients included in this cohort (Table 6)
remained without neurological or psychiatric symptoms
throughout the study; both were aged 4 years in the year
2012. These two cases were initially examined due to
unexplained splenomegaly (associated with cholestatic
neonatal icterus in one case).
Clinical disease course among related patients
Data on this group of patients are summarized in Table 7.
A total of 19 patients were siblings and two were cousins.
Two siblings were involved from eight families, and three
siblings were from one family. It was not possible to fully
assess similarities/differences in some sibling pairs due to
incomplete clinical information (mostly in cases diagnosed
before the year 2000). A similar course of the disease was
reported in siblings from families 1 and 4. Small differ-
ences in age at neurological onset were noted in family 5
(sisters with the late infantile- and juvenile-onset forms,
respectively), and family 2 (sister and brother with the
early infantile- and late infantile-onset forms, respectively)
based on subjective reports from parents’ evaluations.
More precise information was available in family 7
(sisters with juvenile-onset disease) and family 8 (sister
with the juvenile-onset form and brother with the adult-
onset form). In the first sibling pair the clinical course in
the younger sister was clearly milder. In the second pair,
initial neuropsychiatric symptoms occurred 5 years later
in the brother (at age 18) than in the sister (at age 13).
However, disease progression in the brother was more
rapid and he died aged 31; his sister (aged 38) is still alive.





Age at death (†)/age







Mutations in the NPC1 gene
predicted effect on protein
FM1 (Sb) M 1y ? (†)/1y NJa, Hp, HSm
(1 m)
NR HL, BMS ND
M 4 m 4 m (†) NJa, Hp, HSm
(1 m)
NR BMS, AT ND
FM2 (Sb) F 5y ? (†)/5y NJa, HSm (1 m) SRt (22 m) BMS, F(C) c.826T>C/c.3557G>A
p.Y276H/p.R1186H
M 4y ? (†)/4y HSm (1 m) SRt (4y) F(C) c.826T>C/c.3557G>A
p.Y276H/p.R1186H
FM3 (Sb) M 4y 6y (†) NJa (1 m) A, GCt (4y) BMS, MG c.2196dupT/c.3557G>A
p.P733Sfs*9/p.R1186H
F 2y 6y HSm (2y) PMRt (18 m) MG c.2196dupT/c.3557G>A
p.P733Sfs*9/p.R1186H
FM4 (Sb) M DPM 11y (†) NR PMRt (3y) AT ND
M DPM 9y (†) NR SRt, Epi (3y) AT ND
FM5 (Sb) F 4y ? (†)/4y HSm (4 m) PMRg, A (4y) HL ND
F 27y 27 (†) Sm (7y) PMRg (7y) F/V, AT c.352_353delAG/c.3019C>G
p.Q119Vfs*7/p.P1007A
FM6 (Sb) F 14y 14 (†) NR Sp, Epi (7y) AT ND
M 9y 20y (†) Sm (9y) LDs, Epi (9y) BMS, HL ND
FM7 (Sb) F 7y 19y (†) NR PMRg, A (7y) BMS, HL, F/C c.2196dupT/c.2861C>T
p.P733Sfs*9/p.S954L
F 9y 33y (†) HSm (5y) A, Ds (9y) BMS c.2196dupT/c.2861C>T
p.P733Sfs*9/p.S954L
FM8 (Sb) F 21y 38y Sm (21y) A, Ds (13y) F/C c.1210delC/c.1990G>A
p.R404Gfs*45/p.V664M
M 23y 31y (†) Sm (23y) CDc, MDs (18y) BMS, F/C c.1210delC/c.1990G>A
p.R404Gfs*45/p.V664M
FM9 (Sb) F 27 35y (†) Sm (27y) DP (23y) BMS, F/V, MG c.2780C>T/c.2780C>T
p.A927V/p.A927V
F 20 27y Sm (20y) SCH (16) F/V, MG c.2780C>T/c.2780C>T
p.A927V/p.A927V
M 14 23y Sm (14y) LDs, Ds, (14) F/V, MG c.2780C>T/c.2780C>T
p.A927V/p.A927V
FM10 (Cs) M 5y 21y Sm (4y) Ds, (14y) F/I c.2861C>T/c.3557G>A
p.S954L/p.R1186H
F 18y 23y Sm (18y) Ds, A, (13y) BMS, MG c.2861C>T/c.3557G>A
p.S954L/p.R1186H
A ataxia, AT autopsy, BMS bone marrow smear, CDc cognitive decline, Cs cousins, dg diagnosis, DP depression, DPM delayed post-mortem examination (in preserved
tissues), Ds dysarthria, Epi epilepsia, F female, F/C classical biochemical subtype using filipin staining + LDL-cholesterol assay, FM family, F/I intermediate biochemical
subtype using filipin staining + LDL-cholesterol assay, F/V variant biochemical subtype using filipin staining + LDL-cholesterol assay, G gender, GCt gelastic cataplexy,
HL histology of liver, Hp hepatopathy, HSm hepatosplenomegaly, LDs learning disability, m months, MDs memory disorder, MG molecular genetics, ND not done, NJa
neonatal jaundice, NR not reported, PMRg psychomotoric regression, PMRt psychomotoric retardation, Sb siblings, SCH schizophrenia, Sm splenomegaly, Sp spasticity,
y years, *translatin stop codon in 1-leter amino acid code. Note: novel mutations are highlighted in bold font.
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http://www.ojrd.com/content/9/1/140Siblings from family 3 with the early and late infantile-
onset forms showed a 2-year difference in age at neuro-
logical onset, which may be associated with more carefulmonitoring in the younger sister. Disease progression was
also slightly milder in the sister, which might be related to
her treatment with miglustat over the past years.
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onset form and two with the adolescent/adult-onset
form. As soon as NPC was identified in the oldest sister
(presenting with depression, cognitive decline, ataxia
and dysarthria aged 27 years), the younger sister and
brother were examined. At the time of diagnosis the
younger sister had been treated for schizophrenia-like
psychosis for 4 years. Ten years after her first presentation
of psychosis she had no neurological symptoms. The
younger brother had learning difficulties but otherwise
his neuropsychiatric status was normal at diagnosis.
He remained stable up to 21 years of age, after which
he developed sociopathic behaviour, VSGP and ataxia.
Miglustat therapy was commenced in all three siblings
following its approval in 2011. However, the clinical state
of the oldest sister, who was profoundly disabled at the
time miglustat therapy was started, continued to worsen
rapidly until she died aged 35 years. The younger sister
and brother were on miglustat for 1 year and 4 months by
the end of the period of observation.
Two patients with the juvenile-onset form from family
10 were first cousins and carried the same NPC1 gene
mutation. The male cousin was diagnosed at 4 years of
age because of splenomegaly, and presented with his first
neurological symptom (dysarthria) aged 15. Miglustat ther-
apy was commenced in September 2011, and his clinical
state appeared stable at the end of the study. In contrast,
the female cousin exhibited dysarthria and balbuties from
the age of 13 years. Despite commencement of miglustat
therapy in August 2011 her clinical state continued to
worsen; she currently exhibits epilepsy, VSGP, dysarthria,
dysphagia, dystonia, ataxia and cognitive decline.
NP-C SI
The NP-C SI [26] was applied retrospectively in 12 patients
diagnosed during the last 7 years, taking into account the
clinical state at the time of diagnosis. Six patients (cases 12
and 13 in Table 3, cases 19 and 20 in Table 4, and cases 8
and 9 in Table 5) scored > 70 points, indicating a high sus-
picion, four patients (case 12 in Table 2, case 18 in Table 4,
and cases 5 and 6 in Table 5) scored 51–55 points, indicat-
ing moderate suspicion, and two patients (case 7 in Table 5
and case 1 in Table 6) scored 40 points, indicating border-
line suspicion. An asymptomatic patient, case 2 in Table 6,
was assessed prospectively, and scored only 20 points on
the SI. However, genetic analyses were performed anyway,




Disease-specific findings based on BMS analyses were
recorded in 34 patients in our cohort. Examination of
BMS detected foamy histiocytes with variable amountsof autofluorescent ceroid that appeared proportional to
patients’ ages and, eventually, in patients with long-term
NPC, presented in the form of ‘sea-blue’ histiocytes. NPC
histiocytes were distinguishable from those in NPA/B
patients based on birefringence of the stored lipids in
unstained smears. Lipids in NPC storage cells were always
isotropic, but liquid crystals formed in sphingomyelinase
deficiency have a high degree of anisotropy, appearing as a
Maltese-cross type birefringence in polarized light.
Liver biopsy
Findings from combined histological evaluation and histo-
chemical analysis of stored lipids are considered supportive
of a diagnosis of NPC. Histopathological examination of
liver tissue contributed significantly to NPC diagnoses in
four patients in this cohort (case 1 in Table 2, case 4 in
Table 3, and cases 4 and 5 in Table 4). Hepatic sphingo-
myelin storage in NPC was restricted to Kupffer cells;
hepatocytes accumulated other types of lipids (cholesterol,
glycosphingolipids and phosphoglycerides). Again, this
enabled us to distinguish NPC patients from NPA/B
patient samples, where both hepatocytes and Kupffer
cells accumulate sphingomyelin.
Post-mortem analyses
Diagnoses of NPC were based on findings in preserved
post-mortem tissue samples in 16 patients. Spleen samples
consistently showed signs of storage histiocyte infiltration.
Liver changes were minimal, but sometimes showed the
presence of foamy Kupffer cells. However, combined histo-
chemical and electron-microscopic examination detected
lysosomal storage of mixed lipids in hepatocytes. Adrenal
cortex was always unaffected in comparison with NPA/B.
Brain atrophy due to neuronal death was a prominent
finding in a number of cases. Widespread lysosomal
storage not only in cortical neurons, but also in various
subcortical areas (e.g. basal ganglia, cerebellum, brain-
stem and spinal medulla) was considered characteristic
for NPC. Lysosomal storage in brain tissue manifested
histologically as a ballooning of neuronal perikarya and
frequent storage distension of neurites (meganeurites).
Neuroaxonal dystrophy was another typical feature. Neu-
rofibrillary tangles and neuronophagy were demonstrable.
Lysosomal storage in central neurons was dominated by
accumulation of glycosphingolipids, and thus was different
from that seen in histiocytes.
Ultrastructural findings
Ultrastructural methods contributed to diagnoses in post-
mortem tissue samples as well as in liver biopsies. How-
ever, no patients of this cohort were diagnosed primarily
on the basis of ultrastructural skin examination. Lyso-
somal ultrastructure in all affected cell types was lamellar,
loose and concentric, and was arranged as rings, vesicles
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described as polymorphous cytoplasmic bodies, oligo-
membranous bodies or multivesicular bodies. Vesicular
and multivesicular structures appeared specific for NPC.
Biochemical phenotype
Filipin staining and simultaneous LDL-cholesterol esteri-
fication tests were performed in a total of 22 patients.
Non-LDL-cholesterol esterification tests were performed
in two patients diagnosed in 1985 and 1988. In all cases,
results of biochemical testing were supportive of NPC
diagnoses. Overall, based on both filipin staining and
LDL-cholesterol esterification tests, 12 patients (four
with the neonatal/early-infantile form, three with the
late-infantile form, four with the juvenile form and one
with the adult-onset form) were shown to have a ‘clas-
sical’ biochemical phenotype, four patients (one with the
late-infantile form and three with the juvenile-onset
form) had an ‘intermediate’ biochemical phenotype, and
six patients (one with the late-infantile form, three with
the juvenile form and two with the adult-onset form)
had a ‘variant’ biochemical phenotype.
Genetic analysis
NPC1 genotyping analyses indicated pathological muta-
tions in 38 patients from 33 families. NPC2 mutant
genotyping was positive in one patient (patient 9 in
Table 2). In total, 30 different mutations were detected,
14 of which were confirmed as being novel. Twenty out
of 30 different mutations were family specific and 10
were recurrent. Interestingly, among the recurrent muta-
tions there were three that were not described previously
in the literature (p.G343E, p.R411P and c.1812dupT).
Each of these novel mutations occurred in two unrelated
probands in our cohort.
Counting each mutated allele in each family only
once, the most frequent mutant NPC1 allele was p.
R1186H (n = 13), followed by p.P1007A (n = 8), p.S954L
(n = 8) and p.I1061T (n = 4). Using both sequencing
analysis and MLPA, only one pathogenic mutation was
found in heterozygous form in two patients diagnosed
by other methods: p.R1186H in patient 5, Table 2 and
p.I1061T in patient 8, Table 3. Both of these patients
had infantile-onset NPC and presented with a ‘classical’
biochemical phenotype. NPC1 genotypes were determined
indirectly based on parental genetic analyses in two patients
who were diagnosed based primarily on histopathological
findings (patient 3 in Table 2 and patient 5 in Table 3).
Prenatal diagnostics
Although genetic counselling was offered and carried
out in most of the affected families, prenatal diagnostics
for 25% risk of NPC were conducted in only four women
from four families. Filipin staining in combination withLDL-cholesterol esterification assay were performed in
cultivated chorionic villi cells from two foetuses. In the
both cases, results testified to a healthy foetus which
was subsequently confirmed by DNA analysis in the
concerned siblings. After 2005, prenatal testing through
targeted DNA analysis of the familiar NPC1 mutations
in chorionic villi cells was performed in two foetuses
who were both shown to be healthy heterozygotes.
Chitotriosidase activity
Plasma chitotriosidase activity has been measured as a
marker of reticuloendothelial activation at our centre
since 2001, with a reference range of 4.4–89 nmol/h/ml.
Overall, chitotriosidase activity was measured in 20 pa-
tients; the median value across the cohort was 195 nmol/
h/ml. Chitotriosidase was measured in 14 patients at the
time of diagnosis (one early-infantile, two late-infantile,
four juvenile, and five adult-onset patients as well as two
pre-symptomatic cases); results ranged from 39 nmol/h/
ml to 793 nmol/h/ml. Recorded values were in the normal
range in two of the juvenile-onset patients (cases 19 and
20 in Table 4) and two of the adult-onset patients (cases 8
and 9 in Table 5). Elevated values were recorded in the
remaining 16 patients.
Discussion
Data from this observational study in a large cohort of
Czech NPC patients clearly demonstrate the evolution of
the diagnostic process in NPC over the last four decades,
stemming from the rapid adoption of new clinical methods
based on research activities. We also highlight the crucial
role of close collaboration between treating physicians and
specialized diagnostic laboratories and reference centres in
a rare disease like NPC.
Up until 1985 almost all NPC patients, including those
from our centre, were diagnosed exclusively on the basis
of histopathological evidence, often during post-mortem
studies. Preserved tissues were even stored for several
years until attained knowledge allowed diagnosis in three
late-infantile cases. Histological, histochemical and ultra-
structural features allowing the efficient establishment of
diagnoses at the clinico-pathological level were summa-
rized by Elleder in 1989 [40]. Liver findings in seven
patients from this cohort who had neonatal, early-infantile,
late-infantile or juvenile-onset disease were published in
detail in 1984 [13], and an in-depth neuropathological study
of two patients from this cohort who had the early-infantile
onset form was published in 1985 [12].
The introduction of the filipin staining test and choles-
terol esterification assays into clinical practice around
1985 led to a vast improvement in the diagnosis of NPC,
particularly among younger-onset patients. However, these
biochemical methods came with the limitations of being
both labour intensive and time-consuming, and necessitated
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positive diagnoses were seen, and the reliability of findings
was lower among patients with ‘variant’ biochemical
phenotypes. As biochemical tests required referral to a
specialist laboratory, information from histopathological
BMS analyses (e.g. findings of isotropic histiocytes based
on birefringence) proved invaluable in our institution for
selecting patients with a high likelihood of having NPC
for further diagnostic work-up [14]. A histochemical study
of lipid storage in BMS, which included findings from five
patients from this cohort with infantile or childhood-
onset NPC, was published by Elleder in 1983 [15].
Molecular genetic analyses can be performed in DNA or
RNA isolated from blood samples, and are more suitable
for the purposes of genetic counselling and prenatal diag-
nostics. Improvements in the accessibility and accuracy of
genetic profiling together with an increased understanding
of the clinical symptomatology and natural history of NPC
have enabled the earlier detection of the disease in the
Czech Republic, especially among patients with the
adolescent/adult-onset form. In 2010, Poupetova et al.
[4] reported that the birth prevalence of NPC was 0.91
per 100,000 (originally 0.66–0.83 per 100,000 in the
UK, France and Germany). Taking our data into account,
the revised estimate for the birth prevalence for NPC for
the period 1975–2012 is assessed at 0.93 per 100,000. The
detection rate for the Czech Republic population, which
has approximately 10 million inhabitants, is estimated at 1
to 2 patients per year [4].
Reported data on presenting clinical symptoms and
natural course of the disease in the Czech NPC patients
are comparable with the data from other large cohorts
[7,10,27-29]. Our experience that subtle, unspecific
symptoms like learning disabilities, stuttering, clumsi-
ness, fatigue and mood disorder often precede more spe-
cific manifestations of the disease by many years is in
accordance with results of clinical database analysis in a
large group of German and Swiss patients [41].
Notably, a total of 14 novel mutations have been iden-
tified by genetic analysis at our laboratory since 2005.
While the pathogenicity and novelty of these missense
mutations has been confirmed by various in silico methods,
and by cross reference with large mutation databases,
respectively, they are not yet listed in the NPC1 gene
mutations database.
It is interesting to note that the frequency of individual
mutated NPC1 alleles in our cohort differs compared
with previous published information. While data indicate
that p.I1061T is the most frequent mutation in patients of
Western European descent, accounting for approximately
20% of recorded alleles in the UK and France [1], it was
present in only four alleles (6%) in our cohort. The second
most frequent mutation in Europe, p.P1007A, was present
in eight alleles (12%) among our patients. The samefrequency was found for p.S954L, which is also common
in European patients. The most frequent NPC1 mutation
in our cohort was p.R1186H (20%). A founder effect for
this mutation is considered unlikely as it is associated with
at least two different haplotypes (data not shown).
The availability of both clinical data and genetic informa-
tion concerning NPC1 mutations in this cohort allowed
some appraisal of a number of genotype–phenotype corre-
lations. Mutation p.R1186H was present in homozygous
state in a patient with late infantile-onset NPC (patient 12
in Table 3) and in the 4-year-old asymptomatic patient
(patient 1 in Table 6) who has been on miglustat therapy
since 2011. This mutation was also detected in combin-
ation with other missense or frame shift mutations in nine
patients with infantile forms of the disease. Three patients
with juvenile-onset disease were compound heterozygotes
(p.R1186H/p.S954L); the p.S954L mutation is not present
in infantile-onset forms of NPC, but was present in
seven patients with the juvenile-onset form (one being
neurologically asymptomatic up to 15 years of age) and
one adult-onset case. Based on these data, the p.R1186H
mutation can be considered as a severe mutation. In con-
trast, p.S954L may attenuate phenotypic manifestations,
as it occurred in combination with severe mutations such
as deletions or duplications causing frame-shift mutations
in patients with milder forms of disease (juvenile-onset
patients 6, 7 and 15 in Table 4 and adult-onset patient 3 in
Table 5).
Mutation p.P1007A was shown to occur frequently
among patients with late-infantile or juvenile-onset NPC,
indicating a possible moderate effect of the mutation on
patient phenotype. In one adult-onset patient (patient 9 in
Table 5), the mutation was present in combination with
an intronic deletion (c.3592-7_3592-3delCTTTT) that
leads to a transcriptional splicing error resulting in the
deletion of mRNA exon 24. However, the presence of
erroneously as well as correctly spliced transcript cannot
be excluded, and the minor fraction of a correctly spliced
transcript may lead to a milder phenotype.
The most frequent NPC1 mutation in Western Europe
and the US, p.I1061T [27-32], associated mostly with the
juvenile-onset form of the disease, was detected in the
Czech cohort in one patient with the early infantile form
(patient 7, Table 2), two patients with the late infantile
form (patients 8 and 11, Table 3) and in the oldest adult
NPC patient (patient 7, Table 5). In the first case, the p.
I1061T was found in heterozygous form with a likely
deleterious splice mutation, in another patient with late
infantile-onset NPC it was in heterozygous form along
with the very likely severe mutation p.R1186H, mentioned
above, and in the other late infantile-onset patient, diag-
nosed biochemically, the second mutation has not yet
been found. These results support the opinion that the
severe phenotype in our infantile patients was not
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one. The adult patient was a compound heterozygote for
the p.I1061T and p.G992R mutations. The p.G992R in
homozygous state has previously been described in an-
other patient with a non-neuronopathic adult-onset form
of NPC [42]. Together, these findings are in accordance
with the assumed moderate effect of the referred
mutation.
A structured approach to the diagnosis of NPC has
been developed in our centre. If results from a range of
clinical evaluations (assessment of family and personal
history, examination by a clinician familiar with NPC,
abdominal ultrasonography and plasma chitotriosidase
activity) support suspicion of NPC, we usually recommend
bone marrow biopsy. Genetic analyses of NPC genes are
usually undertaken if specific BMS histiocytes are found or
if a clinical suspicion of NPC persists after meticulous
re-evaluation (with filipin testing) in the absence of specific
histiocytes. Novel, emerging diagnostic methods (plasma
oxysterols and/or sphingolipid profiling, next-generation se-
quencing panels) alongside scoring systems such as the
NP-C SI may further enhance this diagnostic algorithm in
the coming years.
Conclusion
Relevant clinical evaluations combined with histopatho-
logical, biochemical and genetic analyses have contributed
to an effective diagnostic process for NPC in the Czech
Republic that has resulted in a surprisingly stable rate of
diagnosis over four decades. The only exception is the
adolescent/adult-onset subgroup, where there has been a
clear proportional rise in the number of cases confirmed
during the last 15 years.
Most patients diagnosed in recent years can gain access
to miglustat therapy, and treatment with this agent has
been commenced in 18 patients at our centre subsequent
to its approval in August 2011. The rational use of im-
proved techniques for detecting and diagnosing NPC may
allow the earlier initiation of disease-specific therapy. Based
on international recommendations for the clinical manage-
ment of NPC it is hoped that this may impact positively on
long-term treatment outcomes [1,8].
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